IVVD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 137847 min ago

@ $4.03

Wydano: 14 vas. 2024 @ 22:29

Zwrot: -42.43%

Poprzedni sygnał: vas. 13 - 21:11

Poprzedni sygnał: Sprzedaż

Zwrot: 1.26 %

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 16:54):

Stats
Dzisiejszy wolumen	43 568.00
Średni wolumen	683 977
Kapitalizacja rynkowa	276.81M
EPS	$0 ( 2024-05-09 )
Następna data zysków	( $-0.370 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.240
ATR14	$0.0150 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Green Julie	Buy	240 000	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	110 700	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	97 500	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	160 000	Stock Option (Right to Buy)
2024-01-19	Adimab, Llc	Sell	5 000 000	Common Stock

INSIDER POWER
6.77
Last 36 transactions
Buy: 9 419 589 \| Sell: 5 442 000

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: 0.17 (neutral)

Signal:(36.129) Neutral

Invivyd, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Invivyd, Inc. Korelacja - Waluta/Towar

-0.16
( neutral )

0.13
( neutral )

0.00
( neutral )

0.22
( neutral )

Invivyd, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2023
Przychody:	$0
Zysk brutto:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2022
Przychody:	$0
Zysk brutto:	$-462 000 (0.00 %)
EPS:	$-2.17

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-5.32

Financial Reports:

No articles found.

Invivyd, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.